Dissecting the Immune Landscape of Acute Myeloid Leukemia
AbstractAcute myeloid leukemia (AML) is a molecularly heterogeneous hematological malignancy with variable response to treatment. Recurring cytogenetic abnormalities and molecular lesions identify AML patient subgroups with different survival probabilities; however, 50–70% of AML cases harbor either normal or risk-indeterminate karyotypes. The discovery of better biomarkers of clinical success and failure is therefore necessary to inform tailored therapeutic decisions. Harnessing the immune system against cancer with programmed death-1 (PD-1)-directed immune checkpoint blockade (ICB) and other immunotherapy agents is an effective therapeutic option for several advanced malignancies. However, durable responses have been observed in only a minority of patients, highlighting the need to gain insights into the molecular features that predict response and to also develop more effective and rational combination therapies that address mechanisms of immune evasion and resistance. We will review the state of knowledge of the immune landscape of AML and identify the broad opportunity to further explore this incompletely characterized space. Multiplexed, spatially-resolved immunohistochemistry, flow cytometry/mass cytometry, proteomic and transcriptomic approaches are advancing our understanding of the complexity of AML-immune interactions and are expected to support the design and expedite the delivery of personalized immunotherapy clinical trials. View Full-Text
Share & Cite This Article
Davidson-Moncada, J.; Viboch, E.; Church, S.E.; Warren, S.E.; Rutella, S. Dissecting the Immune Landscape of Acute Myeloid Leukemia. Biomedicines 2018, 6, 110.
Davidson-Moncada J, Viboch E, Church SE, Warren SE, Rutella S. Dissecting the Immune Landscape of Acute Myeloid Leukemia. Biomedicines. 2018; 6(4):110.Chicago/Turabian Style
Davidson-Moncada, Jan; Viboch, Elena; Church, Sarah E.; Warren, Sarah E.; Rutella, Sergio. 2018. "Dissecting the Immune Landscape of Acute Myeloid Leukemia." Biomedicines 6, no. 4: 110.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.